Most Commonly Isolated Bacteria in Urine and their In Vitro Sensitivity to Antibiotics in Men with Benign Prostatic Hyperplasia


  • Vineta Vuksanovic Institute for Public Health of Montenegro, Montenegro
  • Nataša Terzic Institute for Public Health of Montenegro, Montenegro
  • Danijela Vujoševic Institute for Public Health of Montenegro, Montenegro



Benign prostatic hyperplasia, bacterial infection, antimicrobial susceptibility.


 Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms commonly affect older men. Men with BPH in Podgorica in almost half (47.5%) cases have positive urine culture, out of which 14.2% have polyinfection. Urinary tract infections are most common in the age group 71 to 80 years. Although both groups of men (with and without BPH) are more prone to gram-negative bacterial infections of the urinary tract, K. pneumoniae is significantly more common in men with BPH compared with men without BPH. The results indicate that treatment of men with BPH is much more complex than in men without BPH due to the fact that in the treatment, a number of strains are resistant to levofloxacin (resistance of gram-negative bacteria to levofloxacin at the level of 80.4%, with 89.7% of resistant strains of K. pneumoniae and 73.3% of Ecoli strains, as well as resistance of gram-positive bacteria at level of 24.8%, with resistant strains of enterococci in 64.7% of the strains) and Ž²-lactam antibiotics (53.4% of  isolated gram-negative bacteria synthesize ESBL enzymes out of which K. pneumoniae in up to 89.7% of the strains). Also, men with BPH have multi drug resistant strains in 53.1% of gram-positive bacteria and 79.7% of gram-negative bacteria. Carbapenems still represent a reserve group of drugs that have a good therapeutic effect in 93.2% of urinary tract infections in men with BPH.


Berry SJ, Coffey DS, Walsh PC. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9.

Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989; 15(Suppl.2): S33-50.

Gaynor ML. Isoflavones and the prevention and treatment of prostate disease: is there a role? Cleveland Clinic Journal of Medicine 2003; 70(3): 203-4.

Denis L, Morton MS, Griffiths K. Diet and its preventive role in prostatic disease. European Urology 1999; 35(5): 377-87.

Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Journal of Clinical Endocrinology and Metabolism 2001; 86(2): 724-31.

Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU International 1999; 84(9): 976-81.

Kirby R, Lepor H. Evulation and nonsurgical menagement of benign prostatic hyperplasia. In: Wein A, Kavoussi L, Novick A, Partin A, and Peters C ed. Campbell-Walsh Urology. Philaddelphia, PA: WB Saunders, 2007; p. 2766-802.

Beckman TJ, Mynderse LA. Evoluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc 2005; 80(10): 1356-62.

AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003), chapter 1: diagnosis and treatment recom-mendations. J Urol 2003; 170(2, pt 1): 530-47.

McConnell J, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline. Rockville MD. Agency for Health Care Policy and Research; 1994.

American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia. Linthicum MD: American Urological Association; 2006.

Magiorakos AP, Srinivasan A, Carey R, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection 2012; 18(3): 1-14.

Performance standards for antimicrobial susceptibility testing; M100-S24.

Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 2011; 305(1): 78-86.

Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Treatment for benign prostatic hyperplasia among community dwelling men: The olmsted county study of urinary symptoms and health status. J Urol 1999; 162: 1301-6.

Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the triumph project. Eur Urol 2002; 42: 323-8.

Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol 2000; 38: 563-8.

Jacobsen SJ, Guess HA, Panser L. A population based study of health care-seeking behavior for treatment of urinary symptoms: the Olmsted County study of urinary symptoms and health status among men. Arch Fam Med 1993; 2: 729-35.

Gorelick JI, Senterfit LB, Vaughan EDJ. Quantitative bacterial tissue cultures from 209 prostatectomy specimens: findings and implications. J Urol 1988; 139: 57-60.

Hasner E. Prostatic urinary infection. Acta Chir Scand 1962; 2: 1-5.

Zhu M, Jiang RJ, Kong HS. Emergence of novel variants of gyrA, parC, qnrS genes in multidrug-resistant Klebsiella caused pneumonia. Zhonghua Liu Xing Bing Xue Za Zhi 2013; 34: 61-6.

Pomakova DK, Hsiao CB, Beanan JM. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant. European Journal of Clinical Microbiology & Infectious Diseases 2012; 31(6): 981-9.

Shoma S, Kamruzzaman M, Ginn AN, Iredell JR, Partridge SR. Characterization of multidrug-resistant Klebsiella pneumoniae from Australia carrying blaNDM-1. Diagnostic Microbiology and Infectious Disease 2014; 78(1): 93-7.

Demirdag K, Hosoglu S. Epidemiology and risk factors for ESBL-producing Klebsiella pneumoniae: a case control study. Journal of Infection in Developing Countries 2010; 4(11): 717-22.

Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009; 58: 299-307.

Memon JI, Rehmani RS, Ahmed MU. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. Saudi Med J 2009; 30: 803-8.

Menashe G, Borer A, Yagupsky P. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001; 33: 188-93.

Tuon FF, Kruger M, Terreri M, Sergio R. Klebsiella ESBL bacteremia-mortality and risk factors. Braz J Infect Dis 2011; 15(6): 594-9.

Berry A, Barratt A. Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis. J Urol 2002; 167(2): 571-7.

Alecsandru D, Gestoso I, Romero A, Martinez A, Garcia A, Lobo J. Escherichia coli Multiresistant Meningitis after Transrectal Prostate Biopsy. The Scientific World Journal 2006; 6: 2323-6.




How to Cite

Vineta Vuksanovic, Nataša Terzic, & Danijela Vujoševic. (2016). Most Commonly Isolated Bacteria in Urine and their In Vitro Sensitivity to Antibiotics in Men with Benign Prostatic Hyperplasia. Journal of Analytical Oncology, 5(3),  93–101.